Latest Medical Technology News

4DMedical Limited has secured FDA clearance for CT – VQ™, the first non-contrast CT-based ventilation-perfusion imaging technology, promising to transform lung diagnostics by replacing traditional nuclear scans.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Clever Culture Systems has validated and launched an AI-driven analysis module for smaller contact plates, significantly expanding its pharmaceutical market reach and recurring revenue potential.